These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
179 related articles for article (PubMed ID: 27869670)
1. Homologous Prime-Boost Vaccination with OVA Entrapped in Self-Adjuvanting Archaeosomes Induces High Numbers of OVA-Specific CD8⁺ T Cells that Protect Against Subcutaneous B16-OVA Melanoma. Stark FC; McCluskie MJ; Krishnan L Vaccines (Basel); 2016 Nov; 4(4):. PubMed ID: 27869670 [TBL] [Abstract][Full Text] [Related]
2. Rapid clonal expansion and prolonged maintenance of memory CD8+ T cells of the effector (CD44highCD62Llow) and central (CD44highCD62Lhigh) phenotype by an archaeosome adjuvant independent of TLR2. Krishnan L; Gurnani K; Dicaire CJ; van Faassen H; Zafer A; Kirschning CJ; Sad S; Sprott GD J Immunol; 2007 Feb; 178(4):2396-406. PubMed ID: 17277146 [TBL] [Abstract][Full Text] [Related]
3. Archaeosomes induce long-term CD8+ cytotoxic T cell response to entrapped soluble protein by the exogenous cytosolic pathway, in the absence of CD4+ T cell help. Krishnan L; Sad S; Patel GB; Sprott GD J Immunol; 2000 Nov; 165(9):5177-85. PubMed ID: 11046050 [TBL] [Abstract][Full Text] [Related]
4. Archaeosomes as self-adjuvanting delivery systems for cancer vaccines. Krishnan L; Dennis Sprott G; J Drug Target; 2003; 11(8-10):515-24. PubMed ID: 15203920 [TBL] [Abstract][Full Text] [Related]
5. Archaeosomes induce enhanced cytotoxic T lymphocyte responses to entrapped soluble protein in the absence of interleukin 12 and protect against tumor challenge. Krishnan L; Sad S; Patel GB; Sprott GD Cancer Res; 2003 May; 63(10):2526-34. PubMed ID: 12750276 [TBL] [Abstract][Full Text] [Related]
6. An Archaeosome-Adjuvanted Vaccine and Checkpoint Inhibitor Therapy Combination Significantly Enhances Protection from Murine Melanoma. Stark FC; Weeratna RD; Deschatelets L; Gurnani K; Dudani R; McCluskie MJ; Krishnan L Vaccines (Basel); 2017 Oct; 5(4):. PubMed ID: 29072624 [TBL] [Abstract][Full Text] [Related]
7. Archaeosome adjuvant overcomes tolerance to tumor-associated melanoma antigens inducing protective CD8 T cell responses. Krishnan L; Deschatelets L; Stark FC; Gurnani K; Sprott GD Clin Dev Immunol; 2010; 2010():578432. PubMed ID: 21318177 [TBL] [Abstract][Full Text] [Related]
8. Phosphatidylserine receptor-mediated recognition of archaeosome adjuvant promotes endocytosis and MHC class I cross-presentation of the entrapped antigen by phagosome-to-cytosol transport and classical processing. Gurnani K; Kennedy J; Sad S; Sprott GD; Krishnan L J Immunol; 2004 Jul; 173(1):566-78. PubMed ID: 15210818 [TBL] [Abstract][Full Text] [Related]
9. Intracellular bacterial vectors that induce CD8(+) T cells with similar cytolytic abilities but disparate memory phenotypes provide contrasting tumor protection. Stark FC; Sad S; Krishnan L Cancer Res; 2009 May; 69(10):4327-34. PubMed ID: 19435919 [TBL] [Abstract][Full Text] [Related]
18. Early Treg suppression by a listeriolysin-O-expressing E. coli vaccine in heterologous prime-boost vaccination against cancer. Dai MS; Vassaux G; Xu M; You RI; Hsieh YF; Ouisse LH; Lo KY; Sytwu HK; Chao TY Vaccine; 2012 Nov; 30(48):6903-11. PubMed ID: 22982404 [TBL] [Abstract][Full Text] [Related]
19. Heterologous Prime Boost Vaccination Induces Protective Melanoma-Specific CD8 Ring SS; Królik M; Hartmann F; Schmidt E; Ali OH; Ludewig B; Kochanek S; Flatz L Mol Ther Oncolytics; 2020 Dec; 19():179-187. PubMed ID: 33209978 [TBL] [Abstract][Full Text] [Related]